Stock Analysis Report

Executive Summary

Koninklijke Philips N.V. operates as a health technology company worldwide.


Trading at 26.7% below its fair value

Earnings are forecast to grow 15.73% per year

Pays a high and reliable dividend of 1.89%

Risk Analysis

Has a high level of debt

Snowflake Analysis

Established dividend payer and good value.

Similar Companies

Share Price & News

How has Koninklijke Philips's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: PHG has not had significant price volatility in the past 3 months.

Market Performance

7 Day Return




US Medical Equipment


US Market

1 Year Return




US Medical Equipment


US Market

Return vs Industry: PHG exceeded the US Medical Equipment industry which returned 21.9% over the past year.

Return vs Market: PHG exceeded the US Market which returned 20.3% over the past year.

Shareholder returns

7 Day0.4%1.1%0.5%
30 Day-2.4%0.4%2.0%
90 Day6.9%8.3%9.4%
1 Year26.2%23.7%22.9%21.9%22.8%20.3%
3 Year74.0%63.9%82.5%77.4%50.1%40.4%
5 Year83.1%63.0%116.4%93.7%73.1%54.1%

Price Volatility Vs. Market

How volatile is Koninklijke Philips's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is Koninklijke Philips undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: PHG ($48.61) is trading below our estimate of fair value ($66.35)

Significantly Below Fair Value: PHG is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: PHG is good value based on its PE Ratio (34.3x) compared to the Medical Equipment industry average (47.5x).

PE vs Market: PHG is poor value based on its PE Ratio (34.3x) compared to the US market (18.3x).

Price to Earnings Growth Ratio

PEG Ratio: PHG is poor value based on its PEG Ratio (2.2x)

Price to Book Ratio

PB vs Industry: PHG is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (4.1x).

Next Steps

Future Growth

How is Koninklijke Philips forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHG's forecast earnings growth (15.7% per year) is above the savings rate (1.7%).

Earnings vs Market: PHG's earnings (15.7% per year) are forecast to grow faster than the US market (14.2% per year).

High Growth Earnings: PHG's earnings are forecast to grow, but not significantly.

Revenue vs Market: PHG's revenue (4.8% per year) is forecast to grow slower than the US market (7.6% per year).

High Growth Revenue: PHG's revenue (4.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PHG's Return on Equity is forecast to be low in 3 years time (14.6%).

Next Steps

Past Performance

How has Koninklijke Philips performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PHG has high quality earnings.

Growing Profit Margin: PHG's current net profit margins (6.1%) are lower than last year (7.2%).

Past Earnings Growth Analysis

Earnings Trend: PHG's earnings have grown significantly by 33.9% per year over the past 5 years.

Accelerating Growth: PHG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PHG had negative earnings growth (-9%) over the past year, making it difficult to compare to the Medical Equipment industry average (7.1%).

Return on Equity

High ROE: PHG's Return on Equity (9.4%) is considered low.

Return on Assets

Return on Capital Employed

Next Steps

Financial Health

How is Koninklijke Philips's financial position?

Financial Position Analysis

Short Term Liabilities: PHG's short term assets (€9.4B) exceed its short term liabilities (€6.9B).

Long Term Liabilities: PHG's short term assets (€9.4B) exceed its long term liabilities (€7.4B).

Debt to Equity History and Analysis

Debt Level: PHG's debt to equity ratio (40.5%) is considered high.

Reducing Debt: PHG's debt to equity ratio has increased from 35.8% to 40.5% over the past 5 years.

Debt Coverage: PHG's debt is well covered by operating cash flow (39.2%).

Interest Coverage: PHG's interest payments on its debt are well covered by EBIT (14.2x coverage).

Balance Sheet

Inventory Level: PHG has a high level of physical assets or inventory.

Debt Coverage by Assets: PHG's debt is covered by short term assets (assets are 1.8x debt).

Next Steps


What is Koninklijke Philips's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Upcoming Dividend Payment

Purchase Koninklijke Philips before the 'Buy Limit' to receive their next dividend payment.

Dividend Yield vs Market


Current dividend yield vs market & industry

Notable Dividend: PHG's dividend (1.89%) is higher than the bottom 25% of dividend payers in the US market (1.44%).

High Dividend: PHG's dividend (1.89%) is low compared to the top 25% of dividend payers in the US market (3.73%).

Stability and Growth of Payments

Stable Dividend: PHG's dividends per share have been stable in the past 10 years.

Growing Dividend: PHG's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (64.7%), PHG's dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: PHG's dividends in 3 years are forecast to be well covered by earnings (38.9% payout ratio).

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Frans van Houten (59yo)





Mr. François Adrianus van Houten, also known as Frans, has been the Chief Executive Officer and Chairman of Management Board of Royal Philips at Philips India Limited since April 2011. Mr. van Houten serve ...

CEO Compensation Analysis

Compensation vs Market: Frans's total compensation ($USD5.82M) is below average for companies of similar size in the US market ($USD10.78M).

Compensation vs Earnings: Frans's compensation has been consistent with company performance over the past year.

Leadership Team

François van Houten
Chairman of the Board of Management & CEO8.8yrs€5.39m0.039% 16.9m
Christine Poon
Vice-Chairwoman of the Supervisory Board & Secretary0yrs€154.88kno data
Abhijit Bhattacharya
Executive VP4.3yrs€2.60m0.010% 4.4m
Marnix van Ginneken
Executive VP2.3yrs€1.86m0.0077% 3.4m
Sophie Bechu
Executive VP & Chief of Operations3.4yrsno datano data
Leandro Mazzoni
Head of Investor Relations0.5yrsno datano data
Daniela Seabrook
Chief Human Resources Officer0.08yrsno datano data
Sean Carney
Chief Design Officer8.3yrsno datano data
Roy Jakobs
Executive VP & Chief Business Leader of Connected Care Business1.3yrsno datano data
Jeroen Tas
Executive VP and Chief Innovation & Strategy Officer3.6yrsno datano data


Average Tenure


Average Age

Experienced Management: PHG's management team is considered experienced (3.4 years average tenure).

Board Members

Christine Poon
Vice-Chairwoman of the Supervisory Board & Secretary0yrs€154.88kno data
Orit Gadiesh
Member of Supervisory Board5.8yrs€121.25kno data
David E. Pyott
Member of Supervisory Board4.8yrs€142.25kno data
Jeroen van der Veer
Chairman of the Supervisory Board8.9yrs€179.50k0.0021% 891.9k
Paulus Stoffels
Member of Supervisory Board1.5yrs€46.67kno data
Neelam Dhawan
Member of Supervisory Board7.8yrs€123.75kno data
A. Harrison
Member of Supervisory Board1.3yrs€42.33kno data
Elizabeth Doherty
Member of Supervisory Board0.8yrsno datano data


Average Tenure


Average Age

Experienced Board: PHG's board of directors are considered experienced (4.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Koninklijke Philips N.V.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Koninklijke Philips N.V.
  • Ticker: PHG
  • Exchange: NYSE
  • Founded: 1891
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €40.105b
  • Listing Market Cap: €43.296b
  • Shares outstanding: 889.54m
  • Website: https://www.philips.com

Number of Employees


  • Koninklijke Philips N.V.
  • Philips Center
  • Amstelplein 2
  • Amsterdam
  • Noord-Holland
  • 1096 BC
  • Netherlands


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHGNYSE (New York Stock Exchange)NY REG SH NEWUSUSDJan 1980
PHIADB (Deutsche Boerse AG)NY REG SH NEWDEEURJan 1980
0A2MLSE (London Stock Exchange)NY REG SH NEWGBUSDJan 1980
RYLP.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDDec 1980
PHI1DB (Deutsche Boerse AG)YesCommon SharesDEEURDec 1980
PHISWX (SIX Swiss Exchange)YesCommon SharesCHCHFDec 1980
PHIAENXTAM (Euronext Amsterdam)YesCommon SharesNLEURDec 1980
PHIABIT (Borsa Italiana)YesCommon SharesITEURDec 1980
PHI1XTRA (XETRA Trading Platform)YesCommon SharesDEEURDec 1980
0LNGLSE (London Stock Exchange)YesCommon SharesGBEURDec 1980
PHIAABATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURDec 1980
PHIAWBAG (Wiener Boerse AG)YesCommon SharesATEURDec 1980
PHIA NBMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNDec 1980


Koninklijke Philips N.V. operates as a health technology company worldwide. It operates through Diagnosis & Treatment, Connected Care & Health Informatics, and Personal Health segments. The company offers mother, child care, and oral healthcare products; male grooming and beauty products; food preparation and home care products; and sleep and respiratory care. It provides diagnostic X-ray, integrated clinical, magnetic resonance imaging, computed tomography, and molecular imaging solutions. The company also offers interventional X-ray systems, and imaging and therapy devices for treatment of coronary artery and peripheral vascular disease; imaging products focus on diagnosis, treatment planning, and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; and proprietary software to enable diagnostics and intervention. Further, it provides patient monitoring solutions; patient analytics, precision diagnosis, and clinical decision support systems; therapeutic care products; patient monitoring and therapeutic care consumables; and customer services. Additionally, the company offers healthcare information technology, clinical, and visualization and quantification informatics solutions for radiology, cardiology, and oncology departments; universal data management solutions, picture archiving and communication systems, and integrated electronic medical record systems; clinical and hospital IT platforms; technology-enabled monitoring and intervention, actionable program, cloud-based, and population health management software solutions. It also provides digital frameworks that connect consumers, patients, and healthcare providers in a cloud-based connected health ecosystem of devices, apps, and tools. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 00:15
End of Day Share Price2020/02/19 00:00
Annual Earnings2019/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.